Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Tumor dosimetry with somatostatin receptor-targeted peptide receptor radionuclide therapy (SSTR-targeted PRRT) by 177Lutetium-DOTATATE might contribute to improve follow-up and treatment response of refractory meningiomas. This study aims to evaluate Standard Uptake Value mean (SUVmean) as a tumoral absorbed dose predictive predictive factor and propose semi-automated segmentation method to determine metabolic tumor volume with pretherapeutic 68-Gallium-DOTATOC PET.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 20 patients with meningioma | 20 meningioma patients will be included in this study, 10 of whom will have been treated with Lutathera®. |
| |
| 10 patients will have been treated with Lutathera®. | 10 patients of the 20 will have been treated with Lutathera®. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax | Other | Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the SUVmean (Standard Uptake Value)as a predictive factor of the tumor absorbed dose compared to the SUVmax | Measurements of SUVmean and SUVmax at the lesion level on 68Ga-DOTATOC PET/CT Correlation between SUVmean and max measurements with tumor absorbed doses. | 2 months |
| To propose a semi-automated segmentation | Propose a semi-automated segmentation method for determining metabolic tumor volume with pretherapy DOTATOC labelled with gallium-68 PET. (68Ga-DOTATOC PET) | 1 month |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
- PET scan not available
Not provided
Not provided
20 patients with meningioma will be included in this study, and 10 patients of 20 will have been treated with Lutathera®.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anne-Sophie HUE, MSc | CHRU Nancy | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nuclear medicine Department CHRU de NANCY | Vandœuvre-lès-Nancy | 54511 | France |
Not provided
| ID | Term |
|---|---|
| D008579 | Meningioma |
| ID | Term |
|---|---|
| D009380 | Neoplasms, Nerve Tissue |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009383 | Neoplasms, Vascular Tissue |
Not provided
Not provided
Not provided
Not provided
Not provided
| D008577 | Meningeal Neoplasms |
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009422 | Nervous System Diseases |